Who Paid My Doc
Tami Horner
Obesity Medicine Pinellas Park, FL Medical Doctor
NPI 1376538314 CMS profile 601552
9095 Belcher Rd N, Pinellas Park, FL 33782
General payments
$113
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Tami Horner of Pinellas Park, FL is reported in the CMS Open Payments database as having received $113 across 7 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 27th percentile of Obesity Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $53 | 3 | |
| 2024 | General | $14 | 1 | |
| 2021 | General | $46 | 3 |
Beside peers
- Tami Horner
- Obesity Medicine median
- Middle half of Obesity Medicine
- National median
In program year 2025, general payments to Tami Horner were reported at $53. Among 57 Obesity Medicine profiles paid that year, the median was $178 and the middle half received between $105 and $508.
Show as a table
| Year | Tami Horner | Obesity Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $96 | $24–$339 | $163 |
| 2020 | $0 | $53 | $25–$124 | $114 |
| 2021 | $46 | $113 | $40–$251 | $132 |
| 2022 | $0 | $160 | $53–$375 | $149 |
| 2023 | $0 | $125 | $34–$398 | $160 |
| 2024 | $14 | $136 | $81–$475 | $164 |
| 2025 | $53 | $178 | $105–$508 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
151
Drug cost
$4,806
Branded share of claims
48.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Progesterone Progesterone, Micronized | Brand | 50 | $1,657 | |
| Liothyronine Sodium | Generic | 22 | $1,626 | |
| Np Thyroid Thyroid,pork | Brand | 23 | $1,000 | |
| Levothyroxine Sodium | Generic | 15 | $261 | |
| Spironolactone | Generic | 28 | $207 | |
| Metformin Hcl | Generic | 13 | $55 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obesity Medicine in Florida
Related records
Obesity Medicine in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Obesity Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.